RT Journal Article
T1 SEOM-GECP-GETTHI Clinical Guidelines for the treatment of patients with thymic epithelial tumours (2021).
A1 Remon, J
A1 Bernabé, R
A1 Diz, P
A1 Felip, E
A1 González-Larriba, J L
A1 Lázaro, M
A1 Mielgo-Rubio, X
A1 Sánchez, A
A1 Sullivan, I
A1 Massutti, B
K1 Chemotherapy
K1 Lenvatinib
K1 Multidisciplinary
K1 Nivolumab
K1 Thymic epithelial tumours
AB Thymic epithelial tumours (TET) represent a heterogeneous group of rare malignancies that include thymomas and thymic carcinoma. Treatment of TET is based on the resectability of the tumour. If this is considered achievable upfront, surgical resection is the cornerstone of treatment. Platinum-based chemotherapy is the standard regimen for advanced TET. Due to the rarity of this disease, treatment decisions should be discussed in specific multidisciplinary tumour boards, and there are few prospective clinical studies with new strategies. However, several pathways involved in TET have been explored as potential targets for new therapies in previously treated patients, such as multi-tyrosine kinase inhibitors with antiangiogenic properties and immune checkpoint inhibitors (ICI). One third of patient with thymoma present an autoimmune disorders, increasing the risk of immune-related adverse events and autoimmune flares under ICIs. In these guidelines, we summarize the current evidence for the therapeutic approach in patients with TET and define levels of evidence for these decisions.
YR 2022
FD 2022-02-05
LK http://hdl.handle.net/10668/21041
UL http://hdl.handle.net/10668/21041
LA en
DS RISalud
RD Apr 8, 2025